IGF-1 LR3: Growth Factor Signalling, Anabolism, and Clinical Considerations

IGF-1 LR3 is a long-acting analogue of insulin-like growth factor 1 — a protein that mediates many of the anabolic effects of growth hormone. Its extended half-life and reduced binding to IGF-binding proteins make it clinically distinct from standard IGF-1.

By UAE Peptide Clinic Research Desk

IGF-1 LR3 (Insulin-like Growth Factor 1 Long Arg3) is a long-acting analogue of insulin-like growth factor 1 — a protein that mediates many of the anabolic effects of growth hormone. Its design introduces a 13-amino-acid extension at the N-terminal and an arginine substitution at position 3, together extending its half-life from minutes to hours and reducing its binding to IGF-binding proteins.

Mechanism of Action

IGF-1 acts through the IGF-1 receptor, a tyrosine kinase receptor that activates the PI3K/Akt and MAPK/ERK pathways — governing cell growth, protein synthesis, glucose uptake, and cell survival. IGF-1 LR3 shares this mechanism but its extended half-life allows for more sustained receptor engagement. In clinical settings, it is used to support lean tissue development, recovery, and metabolic function, particularly where GH-axis peptides produce insufficient downstream IGF-1 elevation.

Clinical Considerations

IGF-1 LR3 has a narrow therapeutic window. Because it reduces insulin sensitivity by competing for insulin receptors at high doses, close monitoring of fasting glucose and insulin is essential during any protocol. Protocols typically run short cycles of 2 to 4 weeks with regular bloodwork review.

IGF-1 LR3 is reserved for patients whose bloodwork and clinical profile indicate it as an appropriate addition to their protocol. Our physicians assess every patient individually before prescribing. Explore the protocol at /peptides/igf1-lr3 or book a consultation at /book.